Arch Biopartners Provides MetaMx Development Update

TORONTO, ONTARIO–(Marketwired – Dec. 1, 2015) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced it has successfully completed quality control and pre-clinical validation of a synthesis of MetaMx™ which was produced by a third party chemistry manufacturer in the U.S.

Read more

Arch Biopartners Receives Orphan Drug Designation from FDA for AB569

TORONTO, ONTARIO–(Marketwired – Nov. 13, 2015) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company focused on developing innovative technologies that make a significant clinical impact on patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.

Read more

Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services

TORONTO, ONTARIO–(Marketwired – Oct. 21, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced that it has retained Virtus Advisory Group Inc. (“Virtus”), to develop and implement a strategic investor relations program, which includes enhancing the Company’s exposure among industry stakeholders and investors across Canada.

Read more

Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides

TORONTO, CANADA–(Marketwired – Aug. 5, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,095,541 titled, “Brain Tumor Targeting Peptides”, further protecting MetaMx™, the Company’s peptide based technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).

Read more